NeuroDiversity Consulting LLC
  • Home
    • Our Mission
    • Events
    • Contact Us
  • Autism Attitude
  • Community
    • Stronger Together
    • Race and Disability

NYS Medical Marijuana Law Summary

8/11/2014

0 Comments

 
This post is part of the series Examining the Use of Medical Marijuana for ASD Treatment.

As written the current New York State medical marijuana law does not include ASD in the list of conditions that may be treated with medical marijuana. The following are the only conditions for which medical marijuana use is approved in New York State:

·         Cancer

·         positive status for HIV or AIDS

·         ALS

·         Parkinson’s disease

·         multiple sclerosis

·         damage to the nervous tissues of the spinal cord with objective neurological indication of intractable spasticity

·         epilepsy

·         inflammatory bowel disease

·         neuropathies

·         Huntington’s disease

Included in the New York state legislation is a provision that this list may be amended at will. The legislation also spells out other conditions not necessarily specific to a disease that may be treated with medical marijuana. These include:

·         cachexia or wasting syndrome

·         severe chronic pain

·         severe nausea

·         seizures

·         severe or persistent muscle spasm

Again there is the provision that this list may be amended at will. Furthermore, there is a provision to consider adding the following conditions to the approved medical marijuana conditions list after 18 months:

·         Alzheimer’s

·         muscular dystrophy

·         dystonia

·         post-traumatic stress disorder

·         rheumatoid arthritis

The law does not provide any guidelines as to how to evaluate a given condition for potential inclusion in the approved medical marijuana conditions list.

Patients and providers will be required to be certified and to register in order to prescribe, dispense, and use only those medical marijuana products approved by the state. Certified patients will be required to carry registration cards identifying themselves as certified users of medical marijuana or they will risk prosecution pursuant to existing laws regarding illegal drugs. There is enumerated in the bill regulations for those designated as caregivers of certified patients.

There are also provisions in the law requiring manufacturers and providers to register to manufacture and to provide medical marijuana products. The law also requires these companies to submit their products to laboratory testing in labs approved by the state. It is not clear what standards regarding reporting of levels of active ingredients, content labeling, and reporting of adverse effects manufacturers will be subject to.

While the current legislation does not require insurers to cover medical marijuana the cost of various medical marijuana preparations will be set by the state rather than the manufacturers producing the medical marijuana products. The majority of the language of the bill deals with managing the potential revenue generated by the manufacture and sale of medical marijuana products in New York state.


For more information see ASD and Medical Marijuana References.
0 Comments



Leave a Reply.

    Categories

    All
    504 Plan
    ABLE 2.0
    ABLE Act 2014
    ACE
    Aspergers
    Autism
    Autism Acceptance
    Autism Advisory Board
    Autism Awareness
    Autism Spectrum Disorder
    Autistic Adults
    Autistic Children
    Behavior Intervention Plan
    BIP
    Church
    Cure
    Diagnosis
    Diet
    Disability
    Discipline
    Diy
    Dsm
    Education
    Education Law
    Encouragement
    Epidemic
    Estate Planning
    Faith
    FBA
    Functional Behavioral Assessment
    Homeschooling
    IDEA
    IEP
    Incidence
    Inclusion
    Laws
    Long Term Care
    Mental Health
    Neurodevelopmental Disorder
    Neurodiversity
    New York
    Nha
    Nurtured Heart Approach
    Parenting
    PDD NOS
    PDD-NOS
    Person/people First Language
    Policy
    Prevalence
    Prevention
    Relativism
    Research
    Resilience
    School
    Science
    Sex
    Social Isolation
    Special Education Law
    Special Needs
    Suspension
    Trauma
    Treatment

    Archives

    December 2021
    November 2021
    October 2021
    March 2021
    February 2021
    December 2020
    May 2020
    September 2019
    August 2019
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    August 2017
    July 2017
    May 2017
    April 2017
    December 2016
    May 2016
    April 2016
    January 2016
    August 2015
    June 2015
    February 2015
    August 2014
    July 2014
    June 2014
    May 2014
    September 2013
    July 2013
    June 2013
    November 2012
    July 2012
    March 2012
    February 2012
    January 2012
    November 2011
    October 2011
    August 2011

      RSS Feed

    NeuroDiversity Consulting LLC
    info@neurodiversityconsulting.org

    (315) 760-4358
     Privacy Policy
    Business Credit
    Business Credit by Nav
    Photo from Hayzphotos
    • Home
      • Our Mission
      • Events
      • Contact Us
    • Autism Attitude
    • Community
      • Stronger Together
      • Race and Disability